share_log

Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold, Lowers Price Target to $1

Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold, Lowers Price Target to $1

Canaccord Genuity 将高美药业的评级下调至持有,将目标股价下调至1美元
Benzinga Real-time News ·  2022/08/08 06:14

Canaccord Genuity analyst Edward Nash downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold and lowers the price target from $5 to $1.

Canaccord Genuity分析师爱德华·纳什将高美制药公司(纳斯达克股票代码:GLMD)的评级从买入下调至持有,并将目标股价从5美元下调至1美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发